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Age-related osteoporosis is accompanied by an increase in
marrow adiposity and a reduction in serum insulin-like growth
factor-1 (IGF-1) and the binding proteins that stabilize IGF-1.
To determine the relationship between these proteins and bone
marrowadiposity,we evaluated the adipogenic potential ofmar-
row-derivedmesenchymal stromal cells (MSCs) frommice with
decreased serum IGF-1 due to knockdown of IGF-1 production
by the liver or knock-out of the binding proteins. We employed
10–16-week-old, liver-specific IGF-1-deficient, IGFBP-3 knock-
out (BP3KO) and acid-labile subunit knock-out (ALSKO) mice.
We found that expression of the late adipocyte differentiation
marker peroxisome proliferator-activated receptor  was
increased inmarrow isolated fromALSKOmice.When induced
with adipogenic media, MSC cultures from ALSKO mice
revealed a significantly greater number of differentiated adipo-
cytes compared with controls. MSCs from ALSKO mice also
exhibited decreased alkaline-phosphatase positive colony size
in cultures that were stimulated with osteoblast differentiation
media. These osteoblast-like cells from ALSKO mice failed to
induce osteoclastogenesis of control cells in co-culture assays,
indicating that impairment of IGF-1 complex formation with
ALS in bone marrow alters cell fate, leading to increased
adipogenesis.
In bone marrow (BM),3 cell fate determination is dependent
on the local microenvironment. Cell-cell interactions, hor-
mones, and cytokines all play a role in establishing the timing
and magnitude of lineage commitment and cellular differenti-
ation into adipocytes, osteoblasts (OBs), or osteoclasts (OCs).
OCs and OBs, cells that are essential for bone remodeling, dif-
ferentiate from stem cells of hematopoietic and mesenchymal
origin, respectively (1). Marrow adipocytes are also thought to
arise from mesenchymal precursor cells. Interestingly, oste-
oclastogenesis is closely associated with both osteoblastogen-
esis and adipogenesis. In the former, OBs produce receptor
activator of the NF- ligand (RANKL) and osteoprotegerin,
two critical factors in the OC differentiation scheme. In the
latter, mature adipocytes secrete adipokines and cytokines that
promote OC recruitment and differentiation (2). Moreover, in
many circumstances, commitment of mesenchymal stromal
cells (MSCs) down the adipogenic lineage precludes OB differ-
entiation. Thus, several lines of evidence support the tenet that
osteoclastogenesis is related to adipogenesis in the BM (3, 4).
Increased osteoclastogenesis andBMadiposity are hallmarks
of age-related osteoporosis, a syndrome associated with rapid
bone loss and architectural deterioration that predisposes indi-
viduals to fracture (5). Significant reductions in serum insulin-
like growth factor (IGF-1) levels and osteogenesis are also asso-
ciated with aging (6, 7). However, the relationship between
bioavailable IGF-1 and BM cell fate is largely unknown. Recent
studies in animal models and humans have demonstrated an
important role for the growth hormone/IGF-1 axis in bone
growth and remodeling (8, 9), and lipid metabolism (10).
In vitro, IGF-1 and growth hormone induce proliferative and
differentiative effects on OCs, OBs, and adipocytes (11, 12).
Growth hormone also has lipolytic effects, including induction
of hepatic LDL receptors, inhibition of lipoprotein lipase in adi-
pose tissue, and stimulation of triglyceride hydrolysis to glyc-
erol and free fatty acids (13). IGF-1 increases preadipocyte rep-
lication and differentiation (14). In general, patients with either
growth hormone or IGF-1 deficiencies have increased fat mass
and low bone mass. Turnover indices suggest these individuals
have increased osteoclastogenesis and decreased osteoblasto-
genesis (8, 15–17). This paradox appears to be due, at least in
part, to the physiological bioactivity of IGF-1 that is modulated
by the family of high affinity binding proteins, and an acid-labile
subunit (ALS) that together form IGF binary and ternary
complexes.
To investigate the possible relationship between BM cell fate
and IGF-1 bioavailability, we employedmousemodels of IGF-1
deficiency: liver-specific IGF-1-deficient (LID), IGFBP-3
knock-out (BP3KO), and ALS knock-out (ALSKO). These
mouse models were previously characterized in vivo, and all
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show decreased indices of bone formation in the distal femur
(18) with normal igf1 gene expression in extrahepatic tissues
but variable reductions in circulating levels of total IGF-I (LID,
75%; BP3KO, 40%; andALSKO, 60%). These reductions are due
to lower production of liver IGF-1 in LID, increased peptide
degradation in the absence of the IGF-1 ternary complex (IGF-
1IGFBP-3ALS) in both BP3KOandALSKO, aswell as reduced
stability of the remaining binary complex (IGF-1IGFBP-3) in
ALSKO (19–21). In the current study, we evaluated the poten-
tial of marrow-derived hematopoietic and mesenchymal stem
cells from each model to differentiate into osteoclastogenic,
osteogenic, and adipogenic pathways in vitro.
EXPERIMENTAL PROCEDURES
Animals—Allmouse strains in this studywere backcrossed at
least six generations to a C57BL6/J background. Mice were
housed 4 per cage in a clean mouse facility, fed standard mouse
chow (Purina Laboratory Chow 5001; Purina Mills, St. Louis,
MO), and water ad libitum and kept on a 12-h light/dark cycle.
Animal care and maintenance were provided through Mount
Sinai School ofMedicine, an accredited facility (Association for
Assessment and Accreditation of Laboratory Animal Care).
The Institutional Animal Care and Use Committee of the
Mount Sinai School of Medicine approved all procedures.
Marrow Extraction—BM cells were flushed out from femurs
of male mice using a 26-gauge needle and collected in -mod-
ified minimum essential medium (MEM) culture. An
18-gauge needle was used to achieve single cell suspension.
Cells were then washed in MEM culture and cultured in adi-
pogenic or osteogenic conditions (see below).
Adipogenesis—Adipogenesis was performed using Milli-
pore’s MSC adipogenesis kit according to the manufacturer’s
instructions. Briefly, 106 BM derived MSCs were plated on a
24-well plate and maintained overnight in MSC expansion
media at 37 °C in a 5% CO2 humidified incubator. When cells
reached 100% confluency, adipogenesis induction media (90%
Dulbecco’s modified Eagle’s medium low glucose, 10% fetal
bovine serum, 1 M dexamethasone, 0.5 mM isobutylmethylx-
anthine, 10 g/ml insulin, 100 M indomethacin, and 1 pen-
icillin/streptomycin) was added and replaced every other day.
Recombinant human (rh)IGF-1 (10 nM), rhALS (0.01g/ml), or
rhIGFBP-3 (0.01 g/ml) were added to cultures as indicated.
After 14 days in culture, adipocytes were visualized by oil red
staining; medium was aspirated, and cells were fixed in 4%
paraformaldehyde for 40 min at room temperature. Fixed cells
were thenwashed twicewith 1 phosphate-buffered saline and
incubatedwith oil red solution for 50min at room temperature.
Oil red solution was washed twice with water.
OB Cultures—3  106 MSCs were cultured in MEM sup-
plemented with 10% heat-inactivated fetal bovine serum with
-glycerolphosphate (10 mM) and ascorbic acid (50 mM). Cel-
lular alkaline phosphatase activity was determined using a
para-nitrophenol phosphate-based colorimetric assay. Cul-
tures were carried out for different time points as indicated.
Alkaline phosphate staining was performed using an alkaline
phosphatase kit according to the manufacturer’s instruc-
tions (Sigma-Aldrich). Results were documented using digi-
tal image capture on a microscope (Carl Zeiss AxioCam
HRm, AxioVision version 4.4 software, and SteREO Discov-
ery.V12 microscope). Tiled images were assembled into
merged figures using Adobe Photoshop CS4. Colony counts
and area measurements were made in ImageJ (NIH Image,
version 1.42q, JAVA 1.6.0_10).
Co-cultures—MSC cultures derived from 10–16-week-old
control, LID, ALSKO, and BP3KO male mice were established
as above and plated 3  106 cells/well in 6-well plates. Medium
was replaced every 3 days, and cells were harvested after 14 days
in culture and reseeded 1  105 cells/96-well plate in MEM
supplemented with 10% fetal bovine serum. On the following
day, BM-nonadherent cells cultured overnight with MEM
were spun down, counted, and co-culturedwith the aboveMSC
cultures in a 96-well plate (3  104 cells/well) in MEM sup-
plemented with 10% fetal bovine serum. Co-cultures were then
fixed and stained for tartrate-resistant acid phosphatase
(TRAP) activity 7 days after replating, and TRAP cells con-
taining 3 nuclei under light microscopy were counted as
mature OCs.
TRAP Staining—Cultures were washed two times with 1
phosphate-buffered saline and fixed with 2.5% glutaraldehyde
solution for 15 min at 37 °C. Following two washes with 1
phosphate-buffered saline, a 37 °C warmed TRAP staining
solution (0.05 M sodium acetate, 0.025 M sodium tartrate, 0.125
mg/ml Fast Red Violet LB salt, and 0.125 mg/ml naphthol
AS-MX phosphate) was added for 10–15 min, and then cells
were washed with water.
Gene Expression—Total RNA from BM was extracted using
TRIzol reagent according to the manufacturer’s instructions
(Invitrogen). RNA integrity was verified using Bioanalyzer
(Agilent Technologies 2100 Bioanalyzer-Bio Sizing, version
A.02.12 SI292). One g of RNA was reverse-transcribed to
cDNA using oligo(dT) primers with a reverse transcription-
PCR kit according to the manufacturer’s instructions (Invitro-
gen). Quantitative reverse transcription-PCR was performed
with the QuantiTectTM SYBR green PCR kit (Qiagen) accord-
ing to the manufacturer’s instructions in ABI PRISM 7900HT
sequence detection systems (Applied Biosystems, Foster City,
CA). Each transcript in each sample was assayed three times,
and the fold change ratios between experimental and control
samples were calculated relative to -actin. Sequences of prim-
ers are listed in Table 1.
Purification of rhALS—Chinese hamster ovary cells were
transfected with full-length human ALS cDNA that had been
prepared from a human hepatocyte cDNA library using PCR.
The PCR primers were constructed such that the 3 primer
contained a polyhistidine tag. The PCRproductwas ligated into
pLenti D/TOPO/V5, transfected into 293 cells, and virus-pre-
TABLE 1
Primer sequences
Gene Primers Product size
c/ebp Forward: 5-TGTTGGGGATTTGAGTCTGTG-3 126 bp
Reverse: 5-GGAAACCTGGCCTGTTGTAAG-3
ap2 Forward: 5-AGGAAGGTGAAGAGCATCATA-3 125 bp
Reverse: 5-CATAACACATTCCACCACCAG-3
ppar Forward: 5-AGGCCGAGAAGGAGAAGCTGTTG-3 276 bp
Reverse: 5-TGGCCACCTCTTTGCTCTGCTC-3
rankl Forward: 5-GCTCCGAGCTGGTGAAGAAA-3 82 bp
Reverse: 5-CCCCAAAGTACGTCGCATCT-3
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pared and purified. The virus was used to directly transfect the
Chinese hamster ovary/K1 cells. After determining expression
of the protein by immunoblotting, 3 liters of serum-free condi-
tioned medium was collected, and the protein was precipitated
using 70% ammonium sulfate. The pellet was reconstituted in
0.05 M phosphate, 4 mM EDTA (pH 7.2) and passed over a phe-
nyl-Sepharose column that had been equilibrated with the
same buffer. Fractions containing ALS were eluted with the
same buffer containing 2 mMNaCl. This material, diluted until
the salt concentration was 0.4 M, was applied to a wheat germ
agglutinin affinity column and eluted with 0.5 M N-acetyl-D-
glucosamine. The N-acetyl-D-glucosamine was removed from
the solution using batch extractionwith phenyl-Sepharose. The
purifiedmaterial was then applied to a nickel agarose column in
the same buffer supplemented with 10 mM imidazole. It was
eluted in the same buffer containing 250 mM imidazole. The
eluted protein was analyzed by immunoblotting for ALS and
silver staining. A single band was detected on silver staining
that migrated at the same electrophoretic mobility as the band
that was detected by immunoblotting.
Statistical Analysis—Significant differences among groups
were assessed by one-way analysis of variance. The type I error
rate () was set at 0.05. Differences between groups were com-
pared using post hoc Bonferroni-adjusted multiple compari-
sons (SYSTAT software, SPSS Science).
RESULTS
Effects ofGene Inactivation onOBDifferentiation—Tounder-
stand whether OB cellular behavior is altered in states of IGF-1
complex alterations, we culturedMSCs derived from the different
mouse groups. Cultures from ALSKO mice exhibited similar
numbersofOB-likecolonieswitha2.5-foldsmallerareaofalkaline
phosphatase staining compared with the control (Fig. 1). In con-
trast, neither colony number nor area in OB-like cultures derived
from the other mutant mice differed from the control.
Adipogenesis in BM-derived MSC Is Altered by ALS—To
determine the adipogenic potency ofMSCderived from each of
the four groups, cells were plated in adipogenesis induction
media and the number of adipocytes was determined on day 14.
MSC cultures derived from ALSKO had significantly more oil
red positive cells as compared with cultures derived from con-
trols (Fig. 2). Next, we tested whether addition of rhALS or
rhIGFBP-3 proteins can inhibit adipogenesis of MSC cells
derived from control mice. rhIGF-1, rhALS, or rhIGFBP-3 was
added to 14-day adipocyte cultures derived from MSC of con-
trol mice. Whereas addition of rhIGF-1 led to increased num-
ber of adipocytes as expected, rhALS inhibited the differentia-
tion to adipocytes (Fig. 3). In these conditions, ALS, and not
IGFBP-3, appeared to modulate adipocyte differentiation.
Increased Adipogenic Transcription Factor Peroxisome Pro-
liferator-activated Receptor  (PPAR) in BM from ALS-defi-
cientMice—Tounderstand the reason for increased adipogenic
potential of ALSKO-derived MSCs, we assessed gene expres-
sion levels of CCAAT/enhancer-binding protein- (C/EBP-),
adipocyte protein 2 (aP2), and PPAR transcription factors, in
BM extracted from LID, ALSKO, BP3KO, and control mice
(Fig. 4). Whereas expression levels of the C/EBP- gene were
greater than the control in all mutants, only ALSKO mice
showed a greater BM expression of PPAR, a late marker of
adipocyte differentiation.
Co-culture of OBs Derived from ALSKO with Nonadherent
Cells Derived from Control Fails to Support Osteoclastogenesis—
In view of increased adipogenesis inMSC cultures derived from
ALSKOmice, we explored the potential of ALSKO-derived OB
to support osteoclastogenesis. We established co-cultures of
FIGURE 2. Effects of als and igfbp-3 gene inactivation on bone marrow-
derived adipocyte differentiation. Bone marrow cells were isolated from
8 –10-week-old control (n  5), LID (n  5), ALSKO (n  4), and BP3KO (n  4)
mice and cultured in adipogenic media, as described under “Experimental
Procedures.” Adipocytes were detected by Oil-Red-O staining 14 days follow-
ing adipogenesis induction and are presented as number of adipocytes per














FIGURE 3. Recombinant ALS inhibits adipogenesis of MSC cells. MSC cul-
tures derived from 8 –10-week-old control mice (n  5) were induced with
adipogenic media in the presence of insulin (10 g/ml) and rhIGF-1 (10 nM),
rhIGFBP-3 (1 g/ml), or rhALS (0.01 g/ml). Data are expressed as mean  S.E.














FIGURE 1. Effects of als and igfbp-3 gene inactivation on primary osteo-
blast cultures. Osteoblast cultures derived from control, LID, ALSKO, and
BP3KO 16-week-old male mice were maintained for 14 days and stained for
alkaline phosphatase activity. Stained area was normalized to the control
value. Data are presented as mean  S.E. of n  5 mice per genotype. *, p 
0.05 versus control.
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OBs derived from each of the four groups, with BM-nonadher-
ent cells (enriched in hematopoietic stem cells that give rise to
osteoclasts) derived from control mice (Fig. 5A).We found that
OB cultures derived from ALSKO mice failed to support oste-
oclastogenesis, as evident by few TRAP cells in co-cultures
(Fig. 5B). These data are also supported by primary osteoclast
cultures derived fromALSKOmice, which show reduced num-
bers of osteoclasts in culture (supplemental Fig. 1A). Impor-
tantly, addition of rhALS rescued osteoclastogenesis in these
cultures (supplemental Fig. 1B), whereas addition of IGF-1
failed to attain a rescue (supplemental Fig. 1C). Unlike ALSKO,
OBs derived from BP3KO or LID mice supported osteoclasto-
genesis and showed similar numbers of OCs per well as com-
pared with the control. Together, these data suggest that ALS
has a role in the determination of cell fate in marrow.
DISCUSSION
Although the stabilizing influence of the binary and ternary
complexes on insulin-like growth factor-1 (IGF-1) in serum are
well known, little effort has been devoted to determining what
possible autocrine/paracrine roles the IGF-1 binding proteins
have in marrow (22–25). Binding proteins, such as IGFBP-3
and the ALS, are found locally in tissue and fluid compart-
ments, in and out of serum in both mice and humans (18, 26).
Locally produced IGF-1 predominates over circulating IGF-1 in
maintaining skeletal integrity (27), and both ALS and IGFBP-3
play crucial roles in regulating skeletal function (18).
In the present study, we found that induction of OB-like cul-
tures derived from the BM MSCs of ALSKO mice exhibited
similar numbers of colonies but significantly decreased area of
alkaline phosphatase activity compared with all other groups.
Therefore, despite greater IGF-1 bioavailability, in the absence
of ALS, OB differentiation, and/or proliferation was signifi-
cantly lower. The alkaline phosphatase assay is the gold stand-
ard for measuring OB activity in MSC culture induced for
osteoblastogenesis. However, the possibility exists that the
assay captures MSC, pre-OB, or even preadiopocyte alkaline
phosphatase activity. In fact, a recent study demonstrated that
pre-adipocytes exhibit alkaline phosphatase activity at rela-
tively high levels (28). Regardless, the decreased proliferation
observed in this current in vitro study combined with the
OB/adipocyte lineage allocation proposal, led us to investigate
BM markers of differentiation in IGF-deficient mice.
Marrow adipocytes also differentiate from MSCs. In a study
where C/EBP- was expressed in a dose-dependent manner, it
was shown that OB differentiation occurs with low C/EBP-
levels, whereas adipocyte formation begins as C/EBP- expres-
sion increases (29). We found that BM expression of C/EBP-
was increased 2-fold in all IGF-deficient models. However,
PPAR expression, a latemarker of adipogenesis, was increased
only in BM of ALSKO mice. These data suggest that BM cells,
derived from ALSKO mice, completed adipogenesis, whereas
cells derived from LID and/or BP3KOmice were arrested in an
early preadipogenic stage. Our findings are also in accordance
with a previous study showing that decreased igf1 expression
and translation in MSCs associated with activation of PPAR
transcription factor and suppressed bone formation by regulat-
ing OB/adipocyte lineage allocation to enhance BM adipogen-
esis (30). Low IGF-1 associated with polymorphisms in the
human ppar gene has been linked to low bonemineral density
and obesity (31, 32). A recent study also demonstrated that
reducing IGF-1 by activating ppar in mice with rosiglitazone
increased BM adiposity and suppressed bone formation,
another indication of the importance of BM cell fate (33).
Our results further suggest that in addition to significant
alteration in serum IGF-1, differences in BM levels of ALS may
























FIGURE 4. Expression of adipogenic markers in bone marrow of IGF
mutant mice. Gene expression of c/ebp-, ap2, and ppar was assessed by
real-time PCR in marrow taken from 8 –16-week-old control (n  4), LID (n 
3), ALSKO (n  5), and BP3KO (n  4) mice. Data are expressed as mean  S.E.
*, p  0.05 versus control mice.
FIGURE 5. Co-culture of osteoblasts derived from ALSKO mice with BM-
nonadherent cells derived from control mice failed to support osteoclas-
togenesis. A, schematic of the co-culture protocol. B, osteoblast-like cells
derived from 8 –10-week-old control (n  5), LID (n  5), ALSKO (n  4), and
BP3KO (n  4) mice were co-cultured with BM-nonadherent cells derived
from control mice and stained for TRAP after 7 days in culture. TRAP cells
were counted in 3 wells per mouse per genotype. Data are expressed as
mean  S.E. *, p  0.05 versus control.
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that accompany an increase in marrow adiposity. Ex vivo stud-
ies with MSC cultures derived from ALSKOmice revealed sig-
nificantly more adipocytes as compared with cultures derived
from all othermice.Moreover, we found that addition of rhALS
significantly inhibited adipocyte differentiation in MSC-de-
rived cultures from control mice. Together, these findings sug-
gest that IGF-1 binding to ALS, affects adipocyte progenitor
differentiation.
Another important finding of our study was that OB-like
cultures derived fromALSKOmice failed to support osteoclas-
togenesis of BM nonadherent cells derived from control mice.
This was in sharp contrast to OB-like cultures derived from
BP3KO or LID mice, where TRAP-positive, multinucleated
cells were detected. These in vitro datamay be viewed in light of
fluorescence-activated cell sorter data demonstrating that
receptor activator ofNF- ligand (RANKL) gene expression in
pre-B (B220) cells from BM of ALSKO was significantly less
than that of the control (supplemental Fig. 2).Meanwhile, com-
pared with the control, monocyte differentiation does not
appear to be affected by a lack of ALS (supplemental Fig. 3) and
ALSKOOC function on hydroxyapatite is not inhibited in vitro
(supplemental Fig. 4). When combined with the previous
results, these data implicate ALS as an important regulator of
the adipogenic program directly and OC indirectly.
Our observations could be clinically important becausemar-
row adiposity is a well recognized phenotype observed during
growth and aging in both humans and mice. Recent clinical
imaging studies have revealed inverse relationships between
BM adiposity and both age of the individual and the amount of
bone in the axial and appendicular skeleton (34, 35). Similar
observations have also beenmade in girls with anorexia nervosa
and in mice. In both cases marrow adiposity does not correlate
with body adiposity but is inversely related to levels of bone
formation (36, 37). Decreases in IGF-1 levels during aging are
associated with increases in adiposity in both humans and
mice (21). Due to the difficulties inherent in measuring ALS,
scarce reports of their levels exist in the literature (22). How-
ever, it seems likely that they are also decreased during aging as
has been described in cancer patients (23).Whether BM adipo-
genesis has a direct role in age-related bone loss and increased
fracture risk is a matter of debate. In advanced age, BM adipo-
cytes may reflect passive accumulation of fat as bone is lost and
marrow space increases. Alternatively, MSCs may actively
favor differentiation to the adipogenic over the osteoblastic
lineage with aging.
This study has two limitations of note. First, it was performed
in vitro andmay not reflect accurately the in vivo environment.
Second, the experiments were performed on BM isolated from
long bones of adult (10–16-week-old) male mice; age, gender,
and skeletal site may be critical covariates.
Despite the limitations, we have now demonstrated a link
between the reduced IGF-1 complex formation and increased
adipogenic potential of MSC in vitro. The mutant mice
reported in this study exhibit low bone mineral density (9, 18,
19, 21), which may result from preferential differentiation of
MSCs to the adipogenic lineage. However, extensive studies
demonstrating an essential role for IGF-1 in adipocyte differen-
tiation in vitro have not yet clearly demonstrated why states of
reduced serum IGF-1 levels should be more permissive for adi-
pocyte differentiation in vivo. Our study further reinforces the
tenet that the BM micro-environment includes a strong inter-
action among hematopoietic stem cells, OBs, and adipocytes
and raises the possibility thatALS plays amore active role in the
assignment of cell fate in BM than previously thought.
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